

Harbor-UCLA Medical Center Antibioqram
January 1 through December 31, 2016

Gram negative organisms, % SUSCEPTIBLE

	N	Amp	Amp-Sul	Ceftr	Ceftz	Cefep	Amik	Gent	Levo	Tri/Sulf	Nitro	Mero	Pip-tazo	Cefaz
<i>Acinetobacter baumannii</i>	44	0	82	7	50	63	-	75	77	77	0	80	68	0
<i>Citrobacter freundii</i>	59	-	-	80	76	98	98	95	92	85	97	100	81	0
<i>Citrobacter koseri</i>	56	-	-	100	100	100	100	100	98	100	89	100	100	100
<i>Enterobacter aerogenes</i>	80	-	-	85	84	99	100	100	98	100	15	99	82	0
<i>Enterobacter cloacae</i>	166	-	-	78	78	98	100	99	98	92	42	98	77	0
<i>E. coli</i> : ESBL (-)*	2524	43	51	87	87	88	100	85	72	62	96	100	95	84
<i>E. coli</i> : ESBL (+)	537	0	-	0	0	2	99	51	14	-	88	100	-	0
<i>Klebsiella oxytoca</i>	76	0	66	97	97	93	100	99	97	88	88	100	93	72
<i>K. pneumoniae</i> : ESBL (-)	485	0	80	90	90	91	99	95	94	86	32	99	93	89
<i>K. pneumoniae</i> : ESBL (+)	59	0	0	0	0	0	95	42	51	16	9	97	-	0
<i>Morganella morganii</i>	78	3	6	97	90	100	100	86	78	69	0	100	100	3
<i>Proteus mirabilis</i>	311	82	88	97	97	97	100	91	87	82	0	100	100	96
<i>Providencia stuartii</i>	23	0	22	100	78	95	96	0	22	61	0	100	96	0
<i>Pseudomonas aeruginosa</i>	389	-	-	1	86	89	97	91	80	0	-	92	97	-
<i>Serratia marcescens</i>	67	-	-	96	99	100	99	99	99	100	0	100	-	0
<i>Steno. maltophilia</i>	56	-	-	-	-	-	-	-	92	92	-	-	-	-

* ESBL = extended spectrum beta-lactamase producer

See next page....

Gram positive organisms, % SUSCEPTIBLE

	N	PCN	Amp	Oxa	Clind	Eryth	Vanc	Line	Tri/ Sulf	Tetra	Tige	Cip	Levo	Gent	Nitro
<i>Staph. aureus</i> (MSSA)	936	14	-	64	79	55	100	100	96	94	100	62	63	96	100
<i>Staph. aureus</i> (MRSA)	549	0	-	0	68	14	100	100	91	93	100	17	17	92	98
Coag neg staphylococci	1354	15	-	56	60	37	100	100	4	87	100	69	69	87	100
Viridans streptococci	442	81	-	-	79	65	100	99	-	69	-	-	89	-	-
Group B streptococcus	401	100	100	-	63	58	100	100	-	13	100	-	98	-	-
Group C streptococcus	36	95	-	-	78	72	100	-	-	61	-	-	83	-	-
Group F streptococcus	13	100	-	-	85	92	100	-	-	85	-	-	92	-	-
Group G streptococcus	38	100	-	-	87	76	100	-	-	63	-	-	95	-	-
<i>Strep pneumoniae</i> *	51	90	-	-	80	59	100	-	74	85	-	-	91	-	-
<i>Ent. casseliflavus</i>	13	92	92	-	-	23	0	-	-	100	100	100	100	-	88
<i>Ent. gallinarum</i>	12	100	100	-	-	73	0	-	-	93	-	91	91	-	-
<i>Ent. faecalis</i> (non-VRE)	652	98	98	-	-	7	97	100	-	22	100	79	80	-	98
<i>Ent. faecalis</i> (VRE)	34	77	77	-	-	0	0	96	-	23	100	23	23	-	77
<i>Ent. faecium</i> (non-VRE)	55	61	55	-	-	9	100	100	-	56	100	61	65	-	24
<i>Ent. faecium</i> (VRE)	164	3	4	-	-	0	0	100	-	35	100	0	0	-	9

* 97 % of pneumococci are susceptible to ceftriaxone

Produced by the Clinical Microbiology Laboratory (Robert Yoshimori, Alan Navarro, Sharon Rowland)
and the Department of Infection Prevention and Control